Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.
Fatemeh Esmaeilpour MoallemMohammad Sadra Gholami ChahkandParisa Alsadat DadkhahEftekhar AzarmMehregan ShahrokhiMitra Sadat DeyhimiMohammad Amin KarimiPublished in: Future oncology (London, England) (2024)
Acute myeloid leukemia (AML) is caused by a defective precursor leading to malignant clonal expansion, often with FMS-like tyrosine kinase-3 receptor (FLT3) mutations, particularly internal tandem duplication (ITD), which has a poor prognosis. Quizartinib, a second-generation FLT3 inhibitor, has FDA approval for relapsed/refractory AML with FLT3/ITD mutation. It has shown promise in clinical studies since 2013 due to its excellent oral absorption and potent activity on FLT3. This review explores Quizartinib's mechanism of action, efficacy in monotherapy or combination with chemotherapy, drug interactions, adverse events, resistance mechanisms and future research directions.
Keyphrases
- acute myeloid leukemia
- tyrosine kinase
- poor prognosis
- epidermal growth factor receptor
- allogeneic hematopoietic stem cell transplantation
- long non coding rna
- randomized controlled trial
- acute lymphoblastic leukemia
- anti inflammatory
- radiation therapy
- study protocol
- deep learning
- artificial intelligence
- hodgkin lymphoma